Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation of Georges Ugeux from Board of Directors
Date:9/23/2009

DETROIT, Sept. 23 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) announced that on September 20, 2009, Georges Ugeux resigned as a director of the Company and from the audit, compensation and independent committees of the Board. Mr. Ugeux was the chairman of the independent committee.

In his resignation letter, Mr. Ugeux indicated that he had disagreements with the majority shareholder and senior management of the Company relating to corporate governance and the fiduciary role of independent directors. The Company believes that Mr. Ugeux's disagreements relate to the role of the independent directors going forward in managing the FDA actions previously disclosed by the Company. The current Board, including all the independent directors, believe that management of the FDA actions is and should remain the top priority and focus for the entire management team of the Company, with the entire Board providing the necessary oversight.

All of the members of the current Board, including the independent directors, believe that all shareholders' interests are aligned, and that the Company is moving in the right direction to enable it to resolve the FDA's concerns as expeditiously as possible. In this connection, the Company has engaged highly regarded (i) special FDA counsel to negotiate with the FDA on behalf of the Company and (ii) FDA consultants who are advising and will advise the Company with respect to compliance with FDA requirements. The Board is focused and resolute in its desire to resolve the FDA's concerns, and believes that it is acting in the best interests of all of the Company's shareholders, as resolution of such concerns will benefit all of the shareholders of the Company.

Detroit-based Caraco Pharmaceu
'/>"/>

SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
4. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
5. Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
7. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...ire-USNewswire/ -- The American Dental Association...ration (FDA) to establish appropriate classificati...oncern about the safety of whitening products that...fessional consultation or examination by a dentist...mically based tooth whitening or bleaching agents ...
(Date:11/20/2009)...wire-USNewswire/ -- The following is a statement b...Health Care Association: ,, "The Nevada Health ... Majority Leader Harry Reid for his leadership in ... protecting every Nevada seniors, ongoing access t...rength and viability of our state,s vital frontlin...
(Date:11/20/2009)...ildren with chronic kidney disease often fail to d...sits increasing a child,s risk for serious heart ... Children,s Center and other institutions. A repor... American Society of Nephrology. , Researchers...ing regular doctor visits to readings obtained via...
(Date:11/20/2009)...g 90-day supply, study finds , , FRIDAY,...supply of prescription drugs is up to one-third ch... a new study. , U.S. researchers analyzed 26,85...and 2005, and found that patients who bought a thr...d an average 29 percent in out-of-pocket costs. Af...
(Date:11/20/2009)...es increased food insecurity as many face problem ...swire/ -- Project Bread, the state,s leading anti-...oming annual status report on hunger in the Common...eport, caused by high unemployment, point to 554,0...er. Food insecurity has found its way into middle ...
Breaking Medicine News(10 mins):Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2Health News:High blood pressure easy to miss in children with kidney disease 2Health News:Three-Month Supply Lowers Drug Costs 2Health News:554,000 in Massachusetts Struggle to Put Food on the Table 2Health News:554,000 in Massachusetts Struggle to Put Food on the Table 3Health News:554,000 in Massachusetts Struggle to Put Food on the Table 4
..., Nov. 1 Arete Therapeutics Inc. today,announced ... lead compound,AR9281, for the treatment of hypert...e inhibitor of soluble epoxide hydrolase (s-EH), a...armacokinetics and pharmacodynamics for single asc...
... Nov. 1 Amedica Corporation, an,orthopedic implan...nologies, announced today that Ashok Khandkar, Ph....ice President Finance and Chief Financial,Officer,... Hotel in New York City. Mr. Khandkar and Mr. Gal...
...gland and PHILADELPHIA, November 1, Shire plc (LSE...ty biopharmaceutical company announces results for...ghts - Product sales up 41% to $543.1 million; -...ed to be at least 30% (Q2 guidance: at,least 25%)....
...nfirm environmental toxins play role in autism, as..., Nov. 1 The National Autism,Association (NAA) an...school districts to implement the "Greening Your S...nate the serious,dangers posed to children from da...
...wth Over Same Quarter Last Year - - 20%... - FY08 Revenue Projection Raised - ...ed - - Conference Call to be Held at 10:00 a.m....cal 2008 ended September 30, 2007, up 73% from $1....
...Calif., Nov. 1 The Maverick Saloon will,host a tr...ber 8, 2007 from,4 PM until 7 PM to raise research... that claimed the life of the much loved and respe...yvjoneshouse.com . The proceeds from the show wil...
Other Medicine News:Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 2Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 3Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 3Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 4Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 5Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 6Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 7Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 8Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 9Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 10Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 11Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 12Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 13Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 14Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 15Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 16Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 17Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 18Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 19Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 20Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 21Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 22Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 23Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 24Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 25Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 26Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 27Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 28Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 29Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 30Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 31Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 32Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 33Health News:National Autism Association and Deirdre Imus Environmental Center for Pediatric Oncology Announce National 'Greening Your School' Initiative 2
(Date:11/20/2009)...ov. 20 Soligenix, Inc. (...y), formerly known as DOR BioPharma, Inc., a late-...it has formed a consortium to develop thermostable... acting vaccines. Soligenix received a $9.4 millio... Infectious Diseases (NIAID), a division of the Na...
(Date:11/19/2009)...ov. 19 In a series of ne..., Heska Corporation (Nasdaq: HSKA ) ("Heska" or t...w and improved website. The upgraded site is the ...rogramming to align the site with the company,s ne...go: http://www.newscom.com/cgi-bin/prnh/20000622...
(Date:11/19/2009)...Nov. 19 The D e al m...its Most Admired Corporate Dealmakers for the seco... its Most Admired Dealmaker in pharma/biotech for ...nd divestitures since January 2006. ,, Over the...tfolio with a focus on high-growth, innovation-dri...
Breaking Medicine Technology:Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6Heska Announces Launch of New Website 2Heska Announces Launch of New Website 3The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3Response Times Vary for In Hospital Heart Attacks 53388 1Response Times Vary for In Hospital Heart Attacks 53388 2Blood Transfusions Not Linked to Long Term Problems 53386 1JAG Media Holdings Inc Announces Completion of Acquisition of CardioGenics Inc 53384 1JAG Media Holdings Inc Announces Completion of Acquisition of CardioGenics Inc 53384 2JAG Media Holdings Inc Announces Completion of Acquisition of CardioGenics Inc 53384 3JAG Media Holdings Inc Announces Completion of Acquisition of CardioGenics Inc 53384 4
... 10:00 a.m. today, Thursday, August 16, 2007, MAL... (Nasdaq: AUXL ) today announced that the Company...g Administration ("FDA") to,resume its phase III c...e,for injection), formerly referred to as AA4500, ...ompany will hold a conference call today,August 16...
...plemental New Drug Application in the Fourth ...ug. 16 Cephalon, Inc. (Nasdaq:,CEPH) today announ...cal,trial of FENTORA(R) (fentanyl buccal tablet) [...d with a broad range of chronic non-cancer pain,co...nce on the primary,endpoint. Results across the 12...
Other Medicine Technology:Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 2Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 3Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 4Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 5Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM) 6Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 2Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 3Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 4Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 5
ApexPro CH
ISI Alumi-Hand
TeleRehab™ Advantage
ISI Ultra-Light Specialty Table
Medicine Products: